首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷核子醫學

市場調查報告書

商品編碼

1373403

全球核子造影設備市場 - 2023-2030

Global Nuclear Imaging Equipment Market - 2023-2030

出版日期: 2023年10月18日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

核子造影技術通常稱為核子醫學影像設備，是一種高度發展的影像儀器，用於核醫學領域，用於觀察和評估人體內部的眾多生理結構和過程。這些設備使用微量放射性物質（放射性追蹤劑或放射性藥物）提供內部器官、組織和生理過程的圖像。

核子造影技術對於檢測和監測許多疾病至關重要，例如癌症、心臟病、神經系統問題和骨骼異常。選擇的設備取決於特定的臨床應用和醫療保健專業人員所需的資料。這些機器由合格的放射科醫生和核醫技術人員使用，對於當代醫療保健至關重要。

動力學

增加研究活動

截至2023年6月，英國公司Serac Imaging Systems開發了一款攜帶式高解析度混合伽馬光學相機，目前正在美國進行臨床試驗。 Seracam 影像設備試驗預計將有 25 名參與者參與，持續約六個月。俄亥俄州立大學韋克斯納醫學中心是第二個開展由研究者資助的研究的地點，該研究旨在將使用Seracam 獲得的伽馬圖像與使用當前最先進的核醫學成像伽馬相機捕獲的圖像進行比較，這些影像來自同一名患者同一天，在馬來西亞吉隆坡進行測試後。

該設備使用輻射來掃描放射性同位素，然後將其提供給患者，其方式類似於 X光天文學中使用的衛星，後者最初由萊斯特大學創建。這揭示了身體如何運作的細節，例如是否存在任何阻塞。

技術進步

根據2023 年《歐洲核子醫學和分子成像雜誌》上發表的文章，最新的PET/MRI 系統，例如具有矽光電倍增管(SiPM) 探測器和飛行時間(TOF) 功能的系統，可提供更高的靈敏度與傳統設備相比。此外，合成 MRI 和指紋辨識技術等 MRI 技術的發展，加上人工智慧重建方法，在研究環境中具有很大的應用潛力。這些進步可能會縮短 MRI 獲取資料所需的時間，同時仍能實現功能和解剖成像。

然而，重要的是要記住，即將推出的新一代 PET/MRI 設備將改變這種情況。這些新系統預計將有許多改進，包括使用更大磁鐵和更大直徑孔徑的改進 MRI 系統、更寬的軸向覆蓋範圍，從而提高 PET 靈敏度。此外，這些新設備將配備專門開發的人工智慧軟體，以利用尖端成像序列加快臨床吞吐量。由此將縮短採集時間（25-30 分鐘）並提高 MRI 靈敏度。

成本高

醫療機構必須對 PET 和 SPECT 掃描儀等核子造影設備進行大量前期資本投資。這個價格涵蓋了成像系統本身、安裝以及為設備騰出空間所需的任何基礎設施改造的成本。除初始購買費用外，核成像設備還包括持續維護和營運支出。為了確保設備的準確性和可靠性，這也包括日常維護和校準。

在核子造影程序中使用放射性藥物會增加整體成本，即使它們不屬於設備成本的一部分。放射性藥物的價格可能很高，並且根據所使用的特定示踪劑而變化。

輻射暴露問題

在核子造影操作中，使用稱為放射性藥物或示蹤劑的放射性物質。這些物質產生電離輻射。透過電離輻射從原子中去除強鍵結電子具有足夠的能量，可能會傷害生物組織。當放射性藥物給予接受核子造影的患者時，他們會暴露在電離輻射下。

根據手術類型和所使用的特定放射性藥物，適用不同的輻射暴露程度。儘管風險通常不大，但仍存在一些風險。患者可能會在整個過程中經歷多次核子造影治療，特別是如果他們有持續的醫療問題需要監測。隨著時間的推移，輻射暴露可能會令人擔憂，尤其是對於經常進行成像的人來說。

有關此報告的更多詳細資訊 - 索取樣本

Nuclear imaging technology, commonly referred to as nuclear medicine imaging equipment, is a highly developed imaging instrument used in the field of nuclear medicine to observe and evaluate numerous physiological structures and processes within the human body. These devices provide images of inside organs, tissues, and physiological processes using minute quantities of radioactive substances (radiotracers or radiopharmaceuticals).

Nuclear imaging technology is essential for the detection and monitoring of a number of illnesses, such as cancer, heart disease, neurological problems, and abnormalities of the bones. The equipment selected relies on the particular clinical application and the data that healthcare professionals need. These machines, which are used by qualified radiologists and nuclear medicine technologists, are essential to contemporary healthcare.

Dynamics

Increasing Research Activities

As of June 2023, Serac Imaging Systems, a UK-based firm, developed a portable high-resolution hybrid gamma optical camera, which is currently undergoing clinical trials in the United States. The Seracam imaging device trial is anticipated to involve 25 participants and last about six months. The Ohio State University Wexner Medical Center is the second location to start an investigator-sponsored study to compare gamma images obtained using Seracam with those captured using a current state-of-the-art gamma camera for nuclear medical imaging, from the same patient on the same day, following testing in Kuala Lumpur, Malaysia.

The device uses radiation to scan radioisotopes, which are given to the patient, in a manner similar to that used in satellites used in X-ray astronomy, which was first created by the University of Leicester. This exposes details on how the body functions, such as whether there are any blockages.

Technological Advancements

As per the article published in the European Journal of Nuclear Medicine and Molecular Imaging in 2023, the newest PET/MRI systems, such as those with silicon photomultiplier (SiPM) detectors and time of flight (TOF) capabilities, offer sensitivity levels that are higher than those of traditional devices. Additionally, MRI technology developments like synthetic MRI and fingerprinting technologies, together with artificial intelligence reconstruction approaches, have a lot of potential for use in research settings. These advancements may shorten the time it takes for an MRI to acquire data while still enabling functional and anatomical imaging.

However, it is crucial to keep in mind that the imminent introduction of a new generation of PET/MRI devices will transform the scene. These new systems are anticipated to have a number of improvements, including improved MRI systems using bigger magnets and larger diameter bores, wider axial coverage, and hence increased PET sensitivity. Additionally, these new devices will come with specialized AI software developed to speed up clinical throughput using cutting-edge imaging sequences. Shorter acquisition periods (25-30 min) and increased MRI sensitivity will follow from this.

High Cost

Healthcare facilities must make a substantial upfront capital investment in nuclear imaging equipment like PET and SPECT scanners. This price covers the cost of the imaging system itself, installation, and any infrastructure alterations required to make room for the apparatus. Nuclear imaging equipment includes ongoing maintenance and operational expenditures in addition to the initial purchase. To ensure the accuracy and dependability of the equipment, this also includes routine servicing and calibration.

The use of radiopharmaceuticals in nuclear imaging procedures raises the overall cost even if they are not a part of the equipment cost. The price of radiopharmaceuticals can be high and varies according to the particular tracer that is employed.

Radiation Exposure Concerns

During nuclear imaging operations, radioactive substances known as radiopharmaceuticals or tracers are used. These substances generate ionizing radiation. The removal of strongly bonded electrons from atoms by ionizing radiation has sufficient energy to possibly harm biological tissues. When the radiopharmaceutical is administered to patients undergoing nuclear imaging, they are exposed to ionizing radiation.

Depending on the procedure type and the particular radiopharmaceutical employed, different radiation exposure levels apply. Although the risk is normally modest, there is still some risk involved. Patients may experience many nuclear imaging treatments throughout time, particularly if they have ongoing medical issues that need to be monitored. Radiation exposure over time might be a worry, especially for people who have imaging frequently.

For more details on this report - Request for Sample

Segment Analysis

The global nuclear imaging equipment market is segmented based on product, application, end-user and region.

The PET/CT segment accounted for approximately 45.7% of the market share

As per the Article published in Stat Pearls in 2023, PET/CT (positron emission tomography) is a commonly utilized nuclear medicine imaging method used to examine the staging, therapy response, or recurrence of many malignancies. In addition to mammography, which is still the primary imaging test for identifying and screening cancer, other secondary imaging modalities include ultrasound, MRI, and, under some circumstances, PET/CT. This activity examines the use of PET/CT as an additional imaging technique for the evaluation of breast cancer patients. Furthermore, the interprofessional team's use of PET/CT in the context of breast cancer is highlighted in this activity, along with the indications, imaging method, patient preparation, and use of PET/CT.

The physiological and biochemical information offered by PET is greatly enhanced by the anatomical information provided by CT. It is possible to acquire fused pictures with the combined information on a single screen and to blend from one to the other by modifying the 922 (color) scales thanks to the 919 combining of the two modalities into PET/CT by positioning the two system gantries on a 920 common axis and with a common patient bed.

Geographical Penetration

North America segment accounted for approximately 38.9% of the market share

North America has been a dominant force in the global nuclear imaging equipment market. Nuclear imaging technology is constantly improving, resulting in more accurate and effective imaging, which has fueled market expansion. Particularly common hybrid imaging technologies are PET/CT and PET/MRI, which are used for diagnosis. For instance, in June 2023, at the 2023 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), GE HealthCare plans to introduce SIGNA PET/MR AIR[i]. The business will demonstrate how its cutting-edge AIR technologies may be integrated with the SIGNA PET/MR AIR system to improve diagnostic accuracy, streamline therapy evaluation, and improve patient comfort.

The need for dependable and comprehensive imaging solutions across the patient care journey is highlighted by recent FDA approvals of innovative PET radiotracers and therapeutic methods for high-prevalence disorders like prostate cancer and Alzheimer's Disease. SIGNA PET/MR AIR incorporates distinct GE HealthCare AIR technologies that respond to the changing needs of specific patient populations. These innovations include MotionFree Brain[ii], which reduces motion-related PET picture degradation, AIR Coils, which increases and improves patient comfort, AIR Recon DL, which improves MR image quality and enables scan time reduction, and AIR Coils.

COVID-19 Impact Analysis:

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global nuclear imaging equipment market. Many optional nuclear imaging scans and other non-essential medical procedures were delayed or stopped during the early stages of the pandemic in order to lower the risk of viral transmission and save money on medical services.

This resulted in a sharp decline in the number of nuclear imaging procedures, which had financial repercussions for healthcare facilities and nuclear imaging equipment producers. In order to deal with the increase in COVID-19 cases, healthcare organizations changed their focus. Due to this, healthcare workers, resources, and attention were diverted from tasks unrelated to COVID-19, such as nuclear imaging. Infrastructure developments and investments in new imaging technology were occasionally postponed or cancelled.

Competitive Landscape

The major global players in the market include Siemens Healthcare GmbH, GE Healthcare, Philips Healthcare, Canon Medical Systems Corp, Serac Imaging Systems Ltd, Neusoft Medical Systems Co Ltd., DIGIRAD HEALTH, INC., Mediso Ltd., PerkinElmer, and MILabs B.V.

Key Developments

At Arab Health 2023 in Dubai, United Imaging, a Chinese company, and I-ONE Nuclear Medicine & Oncology Center have partnered to conduct the first research and development of the PET/MR uPMR 790 in the Gulf countries.

Why Purchase the Report?

To visualize the global nuclear imaging equipment market segmentation based on product, application, end-user and region as well as understand critical commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of nuclear imaging equipment market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global nuclear imaging equipment market report would provide approximately 61 tables, 61 figures and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by Application
3.3. Snippet by End-user
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Research Activities
  - 4.1.1.2. Technological Advancements
- 4.1.2. Restraints
  - 4.1.2.1. High Cost
  - 4.1.2.2. Radiation Exposure Concerns
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 7.1.2. Market Attractiveness Index, By Product
7.2. Positron Emission Tomography (PET) Systems*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Positron Emission Tomography/Computed Tomography (PET/CT) Systems
7.4. Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Systems
7.5. Single Photon Emission Computed Tomography (SPECT) Systems
7.6. Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) Systems

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Oncology*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiology
8.4. Neurology
8.5. Others

9. By End-user

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 9.1.2. Market Attractiveness Index, By End-user
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Imaging Centers
9.4. Academic & Research Centers
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Siemens Healthcare GmbH*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. GE Healthcare
12.3. Philips Healthcare
12.4. Canon Medical Systems Corp
12.5. Serac Imaging Systems Ltd
12.6. Neusoft Medical Systems Co Ltd.
12.7. DIGIRAD HEALTH, INC.
12.8. Mediso Ltd.
12.9. PerkinElmer
12.10. MILabs B.V.

LIST NOT EXHAUSTIVE